Form D · Biotechnology
K2 Biolabs, Inc.
Houston, TX · CIK 0001848448
Offering snapshot reported Aug 2, 2023 · SEC filing
- Reported sold
- $616K Offering amount: $3M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 5, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 2, 2023 | Initial | $615,522 | No comparison | 7 | SEC filing |
| Mar 12, 2021 | Initial | $5,500,000 | No comparison | 40 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-488578
Source: Form D, filed Aug 2, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Daniel Clark | Executive |
| Andrew De Somma | Director |
| Gerard Fleury | Director |
| Kieron Jones | Director, Executive |
| Kevin Slawin | Director |
| Clifford J. Stocks | Director |
| Andrew Strong | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2710 Reed Road , Ste. 160
Houston, TX, 77051
Houston, TX, 77051